Morgan Stanley Has Lowered Expectations for Generate Biomedicines (NASDAQ:GENB) Stock Price

Generate Biomedicines (NASDAQ:GENB – Get Free Report) had its price target lowered by equities research analysts at Morgan Stanley from $22.00 to $21.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley‘s target price would indicate a potential upside of 102.51% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings downgraded Generate Biomedicines from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Generate Biomedicines in a report on Friday, October 30th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.20.

Check Out Our Latest Analysis on GENB

Generate Biomedicines Price Performance

Shares of GENB opened at $10.37 on Wednesday. Generate Biomedicines has a 1-year low of $9.68 and a 1-year high of $22.67. The company’s fifty day simple moving average is $13.91 and its 200 day simple moving average is $14.02. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.01 and a current ratio of 5.01.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.18). Generate Biomedicines had a negative net margin of 1,289.97% and a negative return on equity of 151.21%. The firm had revenue of $4.22 million during the quarter. As a group, analysts expect that Generate Biomedicines will post -2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Braidwell LP bought a new stake in shares of Generate Biomedicines in the second quarter valued at about $55,398,000. Banque Pictet & Cie SA bought a new position in Generate Biomedicines during the third quarter worth about $26,631,000. State Street Corp acquired a new stake in Generate Biomedicines in the 2nd quarter worth about $8,883,000. Alps Advisors Inc. boosted its holdings in Generate Biomedicines by 31.4% in the 3rd quarter. Alps Advisors Inc. now owns 170,042 shares of the company’s stock valued at $2,554,000 after purchasing an additional 40,636 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in Generate Biomedicines in the 3rd quarter valued at about $2,189,000.

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

Further Reading

Analyst Recommendations for Generate Biomedicines (NASDAQ:GENB)

Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.